John Edwards

• Executive in Residence

John Edwards brings over 30 years of experience in discovery, development, and global commercialization of biopharmaceuticals. This has involved 10 FDA approved biologics and 8 biotech companies with successful exits. Currently, John is Executive Chair at Metera and senior advisor to a start-up biotech company in the Boston area. Most recently John was Executive Chair at Tilos Therapeutics, where in less than two years he helped advance the company from founding to acquisition in 2019 by Merck. During 2019, two other preclinical-stage companies John helped build also had successful exits for investors, Exonics, and Siamab. Previously, as Executive Chair, John helped lead the growth of F-star from a discovery-stage company to a leading clinical-stage developer of bispecific antibodies, raising over $200M in non-dilutive capital, including several asset-based M&A transactions. As COO, John played a lead role at Adnexus, where the company went from start-up to a $450M acquisition by BMS within 4 years. He then continued as President of the company for the next 3 years, working within BMS during the early days of immuno-oncology. John was Vice President of Sales, Marketing, and Medical Affairs at Transkaryotic Therapies and had a 15-year tenure with Genetics Institute/Wyeth, during which time he built what has become a >$1B global pharmaceutical business in hematology. He started his career in R&D as one of the first employees at Genzyme. John received his M.B.A. from Boston University and his B.S. in Chemical Engineering from the University of Massachusetts at Amherst.